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A multicenter study was conducted to define the most suitable testing conditions for antifungal susceptibility
of dermatophytes. Broth microdilution MICs of clotrimazole, itraconazole, and terbinafine were determined in
three centers against 60 strains of dermatophytes. The effects of inoculum density (ca. 103 and 104 CFU/ml),
incubation time (3, 7, and 14 days), endpoint criteria for MIC determination (complete [MIC-0] and prom-
inent [MIC-2] growth inhibition), and incubation temperature (28 and 37°C) on intra- and interlaboratory
agreement were analyzed. The optimal testing conditions identified were an inoculum of 104 CFU/ml, a
temperature of incubation of 28°C, an incubation period of 7 days, and MIC-0.
Dermatophytes are a group of morphologically and physio-
logically related molds that cause well-defined infections in
vertebrates. The incidence of dermatophytoses has increased
over recent years, particularly in immunocompromised pa-
tients (29, 30, 32, 33). The choice of the proper treatment is
determined by the site and extent of the infection and the
species involved, as well as by the efficacy, safety profile, and
kinetics of the available drugs. For localized nonextensive le-
sions, topical therapies with clotrimazole (CLT) are generally
used. For tinea unguium, scalp ringworm, extensive infections,
or skin lesions with folliculitis, systemic antifungal treatment is
necessary (1, 4, 23, 26). Oral drugs such as itraconazole (ITC)
and terbinafine (TRB) are the antifungal agents currently most
used to treat severe infections (4, 23). Some novel compounds,
such as UR-9825, posaconazole, voriconazole, or ravucon-
azole, also appear to be promising candidates for the treatment
of dermatophytosis (2, 10, 28).
In the in vitro method proposed by the National Committee
for Clinical Laboratory Standards (NCCLS) for testing molds
(25), the dermatophytes were not included. Therefore, it is
necessary to develop a reproducible standardized method for
these important fungi that would lead to protocols for proper
treatment. In recent years, some authors, possibly encouraged
by the development of the above-mentioned reference
method, have published various articles wherein several spe-
cies of dermatophytes have been tested (11, 27, 28, 34). In
these works, different adaptations or modifications of the
NCCLS methods have been assayed, although other tech-
niques have also been used (3, 12, 15). The results obtained
have been clearly contradictory in some aspects, which makes
evident the need for standardization and the development of
reference methods. Recently, we evaluated the activity of 11
antifungal drugs against an important number of strains of
dermatophytes (n  508) by using a microdilution method
(10). In that study the testing conditions adopted were an
inoculum size of 104 CFU/ml, a temperature and time of in-
cubation of 28°C and 7 days, respectively, and the MIC end-
point determination was 50% growth inhibition for azoles and
100% for the rest. It is unknown whether varying the condi-
tions would have changed the results significantly. We have
therefore conducted a multicenter study in order to determine
the most reproducible conditions for testing the antifungal
activity of three of the most commonly used drugs—ITC, CLT,
and TRB—against six frequent species of dermatophytes.
MATERIALS AND METHODS
Study design. Three laboratories participated in the present study. Each one
received the same panel of 60 coded isolates, belonging to six species of der-
matophytes, and two reference strains. Each isolate was tested three times in
each laboratory. The reference strains were tested each time that a set of isolates
was tested in each laboratory. The antifungal agents tested were ITC, CLT, and
TRB. We used a broth microdilution method according to a standard protocol.
The protocol included a detailed description of the parameters to be evaluated,
which were, briefly: (i) two inoculum sizes (ca. 103 and 104 CFU/ml); (ii) two
temperatures of incubation (28 and 37°C); (iii) three incubation times (3, 7, and
14 days); and (iv) two MIC endpoints (50 and 100% growth inhibition).
Test organisms. A total of 60 well-characterized clinical isolates were tested.
They included 10 strains of each of the following species: Trichophyton rubrum,
Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum gypseum, Mi-
crosporum canis, and Epidermophyton floccosum. Each isolate was maintained as
a water suspension at room temperature at each center, until testing was per-
formed. Aspergillus fumigatus NCPF 7099, which is resistant to ITC (6, 31), and
Paecilomyces variotii ATCC 36257, were included as reference strains. The MICs
for these isolates were as follows: CLT (1 to 2 g/ml), ITC (32 g/ml), and TRB
(4 to 8 g/ml) for A. fumigatus NCPF 7099 and CLT (0.01 to 0.06 g/ml), ITC
(0.01 to 0.03 g/ml), and TRB (0.03 to 0.06 g/ml) for P. variotii ATCC 36257.
Medium. A single lot of RPMI 1640 broth (Gibco-BRL, Izasa, Barcelona,
Spain) with L-glutamine and without sodium bicarbonate was used. The medium
was buffered to a pH 7.0 at 25°C with 0.165 M morpholinepropanesulfonic acid
(Sigma, Barcelona, Spain). Sterility control of each bottle was performed prior to
use in each laboratory.
Antifungal agents. ITC (Janssen Research Foundation, Beerse, Belgium),
CLT (Química Farmaceu´tica, Bayer, Barcelona, Spain), and TRB (Novartis,
Basel, Switzerland) were provided by the manufacturers as standard powders. All
drugs were dissolved in 100% dimethyl sulfoxide to obtain stock solutions of
1,600 g/ml for ITC and CLT and of 4,000 g/ml for TRB. Drug dilutions were
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performed by an additive twofold drug dilution scheme described in the NCCLS
reference method (25) at 100 times the strength of the final test concentration,
followed by further dilutions (1:50) in RPMI medium to yield twice the final
strength required for the test. The final drug concentrations were 16 to 0.01
g/ml for ITC and CLT and 4 to 0.0039 g/ml for TRB.
Preparation of inocula. Preparation of inoculum suspensions was based mainly
on the NCCLS guidelines (25) and described previously (10). The isolates were
subcultured onto potato dextrose agar (PDA) plates at 28°C. Stock inoculum
suspensions of each isolate were prepared for each experiment from 7- to 14-
day-old cultures grown on PDA. The fungal colonies were covered with ca. 10 ml
of distilled water, and suspensions were made by gently probing the surface with
the tip of a Pasteur pipette. The resulting mixture of conidia and hyphal frag-
ments was withdrawn and transferred to a sterile tube. Heavy particles were
allowed to settle for 5 to 20 min, and the upper homogeneous suspensions were
collected and mixed with a vortex mixer. The densities of these suspensions were
adjusted with a spectrophotometer at a wavelength of 530 nm to obtain two types
of standardized inocula: (i) 80 to 85% transmission (T) and (ii) 65 to 70% T.
These stock suspensions were diluted 1:50 in RPMI medium to obtain the final
inoculum sizes, which ranged from 2  103 to 6.8  103 CFU/ml (low inoculum)
and from 1.2  104 to 6  104 CFU/ml (high inoculum), respectively. Inoculum
quantification was performed in each laboratory by plating 0.01 ml of a 1:100
dilution of the adjusted inoculum on PDA plates. The plates were incubated at
28°C and were examined daily for the presence of fungal colonies. Colonies were
counted as CFU/milliliter when growth became visible.
Test procedure. The broth microdilution tests were performed according
mainly to the NCCLS guidelines for testing filamentous fungi (25), and as we
described in a previous study (10). Microdilution plates (96 U-shaped wells;
Izasa, Barcelona, Spain) were prepared and frozen at 70°C in each laboratory
until needed. Rows 2 to 12 contained the series of drug dilutions in 100-l
volumes, and row 1 contained 100 l of drug-free medium, which served as the
growth control. Each well was inoculated on the day of the test with 100 l of the
corresponding inoculum. This step brought the drug dilutions and inoculum size
to the final test concentrations given above.
Incubation and determination of MIC endpoints. The microplates were incu-
bated at 28 and 37°C and were read at 3, 7, and 14 days of incubation. The MICs
were determined by visual inspection of the growth inhibition of each well
compared with that of the growth control (drug-free) well. Two MIC endpoints
were determined for each isolate and testing condition. The wells were given a
numerical score as follows: (i) 0, optically clear or 100% inhibition of growth
(designated MIC-0); and (ii) 2, ca. 50% reduction in growth (designated MIC-2).
Analysis of the results. All of the MICs were repeated three times in each
laboratory, and the modal or median (when the three values were different) MIC
of the three values was considered for agreement determination. Discrepancies
of no more than two dilutions between the modal or median MICs obtained in
the three laboratories were used to obtain the percent values of agreement. The
percentage of MIC endpoints within two dilutions (e.g., 0.25, 0.5, and 1 g/ml
would be considered in agreement, and 0.25, 0.5, and 2 g/ml would not) for each
combination of isolate, drug and testing condition was determined. The differ-
ences were calculated between the two percentages of agreement for each vari-
able (inoculum, temperature, and endpoint criteria) and with each drug-isolate
pair. Comparisons of proportions were performed by chi-square test or Fisher
exact test as appropriate. A two-tailed P value of  0.05 was considered to be
significant.
The intralaboratory agreement was evaluated for each combination of isolate,
drug, and testing condition. A total of 60 triplicate MICs were obtained in each
laboratory for each combination, i.e., 180 triplicate MICs (540 values in total).
MICs were considered to be in agreement when the differences between the
highest and the lowest values (of the three values) were not greater than two
dilutions (example given above).
RESULTS
All isolates produced clearly detectable growth only after 7
days of incubation. Therefore, the first determination of MIC
endpoints was only possible after that time for all testing con-
ditions.
Inoculum reproducibility. A total of 540 inoculum prepara-
tions from the three laboratories, for each of the two inoculum
sizes, were analyzed. The CFU/ml ranges for 90% of the inoc-
ulum size values were of 2  103 to 5.9  103 CFU/ml for the
low inoculum (80 to 85% T) and of 2.5  104 to 6.8  104
CFU/ml for the high inoculum (65 to 70% T). The reproduc-
ibilities of the six species for the two inocula (low and high)
were: E. floccosum, 93.4 and 81.1%; M. canis, 85.5% for both;
T. rubrum, 92.1 and 85.5%; M. gypseum, 87 and 98.8%; T.
tonsurans, 97.8 and 98.8%, and T. mentagrophytes, 83.4 and
96.1%, respectively.
Interlaboratory agreement. We analyzed a total of 8,640
modal or median MICs for the 60 isolates in each center or a
total of 25,920 values across the species from the three labo-
ratories. The percentages of interlaboratory agreement are
summarized in Table 1. The results are stratified by antifungal
agents and the three testing conditions.
For CLT, the highest interlaboratory agreements (82 to
88%) were achieved when the high inoculum was used and the
microplates were incubated at 28°C. In general, these condi-
tions gave significantly better results than when the low inoc-
ulum or an incubation temperature of 37°C was used. At 37°C,
no significant differences were observed when the inoculum
density, the temperature, or the scoring criteria varied. The
only exception to this was when the combination of 7 days and
MIC-0 with high inoculum was compared with that at low
inoculum (73 versus 56%). At 28°C, significantly higher repro-
ducibility was observed when the higher inoculum was com-
pared with the lower under these the three combination of
conditions: MIC-2 and 7 days (82 versus 50%), MIC-0 and 7
days (88 versus 55%), and MIC-0 and 14 days (87 versus 75%).
The results also improved at the two scoring criteria MIC-0
and MIC-2 when 14 days were compared with 7 days (77 versus
50% and 75 versus 55%, respectively).
In general the results obtained with ITC were not as good as
with the other two drugs. The best reproducibility achieved
(88%) was when the following testing conditions coincided:
high inoculum, MIC-0, 7 days of incubation, and 28°C. With
this drug the worst reproducibility (12%) was achieved, with
the low inoculum, MIC-2 and 28°C. In general, MICs obtained
with the high inoculum provided higher levels of agreement
TABLE 1. Interlaboratory agreement among three laboratories of




Low High Low High
CLT MIC-2/7 50 82 60 73
MIC-2/14 77 82 68 75
MIC-0/7 55 88 56 73
MIC-0/14 75 87 67 75
ITC MIC-2/7 12 60 58 63
MIC-2/14 42 77 42 64
MIC-0/7 67 88 20 57
MIC-0/14 24 47 43 67
TRB MIC-2/7 100 94 98 97
MIC-2/14 100 95 93 90
MIC-0/7 98 100 98 95
MIC-0/14 100 98 93 93
a MIC-2 and MIC-0, 50 and 100% inhibition of growth, respectively; 7 and 14
refer to the days of incubation.
b Low, inoculum density of ca. 103 CFU/ml; high, inoculum density of ca. 104
CFU/ml.
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(47 to 88%) than MICs obtained with the low inoculum (12 to
67%) for all testing conditions (P  0.05). The only exception
was for MIC-2, 7 days at 37°C, where agreement was similar
when both inocula were compared.
Excellent reproducibility (90 to 100%) was observed among
the three laboratories with TRB, regardless of the inoculum
size, incubation time, temperature, or endpoint criteria. In
general, there were no significant differences when the differ-
ent parameters were evaluated. The only exceptions were the
combination of low inoculum and 14 days of incubation, which
agreed better at 28°C than at 37°C, and the combination high
inoculum, 37°C, and MIC-2, which were more reproducible at
7 days than at 14 days of incubation (P  0.05).
Intralaboratory agreement. The intralaboratory agreement
for three drugs against the 60 strains of dermatophytes and for
each testing condition are summarized in Table 2. In general,
intralaboratory reproducibility was high for the three drugs
under all testing conditions, ranging from 87 to 100% of agree-
ment. TRB showed an excellent overall agreement (98 to
100%), whereas azoles showed slightly lower results, from 85 to
96% in the case of ITC and from 88 to 97% in the case of CLT.
Antifungal susceptibility by using optimized conditions. Ta-
ble 3 summarizes the MICs of the three antifungal drugs
against the 60 strains of dermatophytes obtained in the three
laboratories under the best conditions (100% growth inhibition
criterion [MIC-0], 7 days of incubation, a low inoculum, and a
temperature of incubation of 28°C). In general, the three drugs
were very active against all of the species tested. Overall, TRB
was the most active, showing the lowest geometric mean MIC
(0.04 g/ml). CLT and ITC also showed good antifungal ac-
tivity, their geometric mean MICs being similar (0.21 and 0.42
g/ml, respectively).
DISCUSSION
The performance of antifungal susceptibility testing for der-
matophytes is still technically difficult due to the morphological
characters of these fungi. Some of the species, especially the
anthropophilic ones, sporulate with difficulty, which is more
accentuated after repeated subcultures. When this occurs it is
very difficult to prepare conidial inocula. It is important to use
culture media that induce abundant fungal sporulation. Re-
cently, Jessup et al. (17) demonstrated that oatmeal and rice
agar are good media to enhance sporulation of T. rubrum. In
the present study we used PDA, also recommended by the
NCCLS reference method (25), which in preliminary studies
has proven to work better than Sabouraud dextrose agar (data
not shown), and in general we have obtained good results.
Additionally, these fungi can develop two types of conidia,
macro- and microconidia, whose sizes are considerably differ-
ent. The different proportions of both that can be included in
a mixture at a given transmittance can influence enormously
the number of CFU/milliliter resulting in complicated inocu-
lum standardization. Because of this, we demonstrated in pre-
vious works the lack of correspondence between density and
number of particles in different filamentous fungi (16). Here,
we have used two inocula measured spectrophotometrically,
which allowed us to obtain suspensions with no particularly
significant dispersion in the number of particles.
TABLE 2. Intralaboratory agreement among three laboratories of




Low High Low High
CLT MIC-2/7 94 97 93 94
MIC-2/14 95 97 88 96
MIC-0/7 94 95 93 93
MIC-0/14 94 97 89 96
ITC MIC-2/7 87 93 88 90
MIC-2/14 93 94 88 90
MIC-0/7 91 94 87 92
MIC-0/14 93 96 88 85
TRB MIC-2/7 100 100 100 100
MIC-2/14 99 100 100 100
MIC-0/7 100 100 100 100
MIC-0/14 100 100 100 98
a MIC-2 and MIC-0, 50 and 100% inhibition of growth, respectively; 7 and 14
refer to the days of incubation.
b Low, inoculum density of ca. 103 CFU/ml; high, inoculum density of ca. 104
CFU/ml.
TABLE 3. Antifungal susceptibility results for 60 strains of
dermatophytes obtained in three laboratories under optimal
testing conditions
Species MICparametera
MIC (g/ml) for antifungal agent:
CLT ITC TRB
E. floccosum Range 0.01–0.5 0.03–1.0 0.01–0.125
GM 0.14 0.26 0.04
50% 0.25 0.25 0.03
90% 0.25 0.5 0.06
M. canis Range 0.03–0.5 0.06–2 0.01–0.5
GM 0.11 0.37 0.06
50% 0.125 0.25 0.06
90% 0.25 1 0.125
M. gypseum Range 0.125–2 0.03–2 0.03–0.125
GM 0.55 0.54 0.06
50% 0.5 0.5 0.06
90% 1 1 0.06
T. tonsurans Range 0.01–2 0.06–1 0.0078–0.06
GM 0.27 0.46 0.03
50% 0.25 0.5 0.03
90% 1 1 0.06
T. mentagrophytes Range 0.06–2 0.06–2 0.01–0.06
GM 0.29 0.52 0.03
50% 0.25 0.5 0.03
90% 1 2 0.06
T. rubrum Range 0.03–0.5 0.06–2 0.01–0.06
GM 0.13 0.42 0.03
50% 0.125 0.25 0.03
90% 0.25 1 0.03
All organisms Range 0.01–2 0.03–2 0.0078–0.5
GM 0.21 0.42 0.04
50% 0.25 0.5 0.03
90% 1 1 0.06
a GM, geometric mean; 50 and 90%, MICs at which 50 and 90% of the isolates
tested, respectively, are inhibited.
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Various procedures for testing dermatophytes have been
evaluated by different authors (3, 15, 24), but their results have
showed great variability. This is likely due to the lack of stan-
dardization of different parameters that can influence MICs
determination, such as inoculum (14), length and temperature
of incubation (7, 20, 21), and endpoint criteria (9). After a
general agreement has been achieved in the optimal conditions
for in vitro testing of yeasts and some important filamentous
fungi (8, 13), those for dermatophytes need to be defined. In
spite of the numerous studies devoted to these fungi, there are
no data reported as a result of collaborative studies. To our
knowledge, the present study represents the first interlabora-
tory evaluation of dermatophytes testing. In general, we have
followed the recommendations of the NCCLS for testing fila-
mentous fungi (25). These include the use of a broth microdi-
lution method, mainly the same drug dilution schema, buffer,
and culture medium; the inocula were also standardized, as
was mentioned earlier, by a spectrophotometric method, and
the same visual evaluation of MIC readings were used. How-
ever, in the present work we have also evaluated other drugs
(such as TRB and CLT), other parameters (such as incubation
temperatures of 28 and 37°C), and two endpoint criteria to
define MIC azoles. Previous studies have demonstrated that
buffered RPMI 1640 medium allows adequate growth of fila-
mentous fungi, including dermatophytes (9, 22, 27). Our study
has also confirmed this because this medium produced a suit-
able visible growth for all strains tested. It is well known that
the inoculum size exerts a great influence on the MICs (14). In
the present study, we compared two inoculum densities, i.e.,
that proposed by the NCCLS method (104 CFU/ml) and a
lower one (103 CFU/ml) that we used in a previous study,
testing an important number of strains of T. rubrum (11). The
MICs of ITC and CLT obtained in the present study with the
highest inoculum clearly showed a better reproducibility than
those obtained with the low inoculum, whereas with TRB no
differences were observed. Our results agree with those of
Norris et al. (27), who, also testing dermatophytes, demon-
strated that inoculum size did not affect TRB MICs. The fact
that the inoculum size can influence the MICs of some drugs
but not others has also been reported by other authors, e.g.,
Gehrt et al. (14), testing filamentous fungi, observed a signif-
icant effect of inoculum density on ITC and flucytosine MICs
but not on amphotericin B and miconazole MICs. It seems that
the effect of inoculum size MICs for filamentous fungi is de-
pendent upon the antifungal agent tested, and it may be re-
lated to the mechanisms of the action of the antifungal agent.
It is well known that the majority of dermatophyte species
show an optimal growth between 4 and 15 days of incubation
at 28 to 30°C (5). However, various authors have proposed
higher temperatures such as 35 or 37°C and different times of
incubation, ranging from 3 to 20 days, for testing these fungi (2,
3, 27, 28). In one of these studies, it was proven that the
optimal time of incubation depended on the species tested (2),
(from 6 to 10 days for Microsporum spp., E. floccosum, and T.
mentagrophytes and from 15 to 20 days for T. rubrum and T.
verrucosum). Interestingly, Perea et al. (28) also demonstrated,
by using a macrodilution method for testing dermatophytes,
that the time of incubation required to obtain adequate growth
depended on the dissolvent of the drugs. For example, when
distilled water was used, the time of incubation was shorter (48
to 72 h) than when polyethylene glycol was used (10 to 14
days). In our study, a higher reproducibility was achieved for
CLT and ITC at 7 days rather than at 14 days and at 28°C
rather than at 37°C, whereas for TRB the temperature and the
time of incubation did not significantly influence MICs. The
NCCLS document (25) recommends a 50% inhibition to de-
fine azole MICs. However, recently, Espinel-Ingroff et al. (9)
demonstrated that a more stringent MIC determination crite-
rion (MIC-0 or 100% inhibition) can differentiate between
susceptible and resistant Aspergillus isolates to ITC or to other
investigational drugs, i.e., posaconazole, ravuconazole, and
voriconazole. Also, other collaborative studies have showed an
excellent interlaboratory agreement with this criterion of read-
ing (6, 7, 22). In our case, higher reproducibility was obtained
when MICs were scored as MIC-0 than as MIC-2. This was
more evident with azoles, and especially with ITC, when a high
inoculum at 28°C and 7 days of incubation was assayed. In the
present study, the reproducibility of azoles, under certain con-
ditions, was low. This agrees with several collaborative studies
testing yeasts and filamentous fungi, which demonstrated that
azole MICs were extremely variable, being enormously influ-
enced by testing conditions (13). Similar results were obtained
in a multicenter study performed by Espinel-Ingroff et al. (8),
who, testing filamentous fungi, found the lowest intra- and
interlaboratory agreement for ITC (59 to 79% and 59 to 91%,
respectively). Although several studies have been published on
the in vitro susceptibility of the three drugs tested here (15, 17,
18, 24, 27), it is difficult to compare results due to variability in
the different methods and conditions under which they were
performed. We observed in general that TRB was more active
than CLT and ITC. This agrees with previous reports, which
showed the efficacy in vitro of this allylamine (3, 17, 18). How-
ever, for ITC we obtained MICs that were within the range of
expected concentrations in nail with daily oral doses of 100 to
200 mg (4, 19). Similar results were obtained by Korting et al.
(18), who tested numerous isolates of T. rubrum and T. men-
tagrophytes from patients with tinea unguium, also by a mi-
crodilution method.
In conclusion, we propose as optimal conditions for evalu-
ating the in vitro antifungal susceptibility of dermatophytes an
incubation time of 7 days, a temperature of 28°C, an inoculum
of ca. 104 CFU/ml, and an MIC endpoint of 100% growth
inhibition. However, further studies are needed in order to
better define these conditions, especially those of the azoles.
Additionally, MICs obtained need to be correlated with clini-
cal outcome to demonstrate the true value of these data.
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